Stock Buyback Plan Declared by Haleon (LON:HLN)

Haleon (LON:HLN) declared that its board has initiated a stock buyback program on Thursday, October 29th, RTT News reports. The company plans to repurchase £500 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 1.8% of its shares through open market purchases. Share repurchase programs are typically an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages have commented on HLN. Deutsche Bank Aktiengesellschaft cut their price target on shares of Haleon from GBX 335 to GBX 320 and set a “sell” rating for the company in a research note on Wednesday, September 9th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 400 target price on shares of Haleon in a report on Friday, July 31st. Berenberg Bank raised their target price on Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Royal Bank Of Canada boosted their price target on Haleon from GBX 370 to GBX 390 and gave the company a “sector perform” rating in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Haleon has an average rating of “Hold” and an average price target of GBX 387.80.

Haleon Price Performance

Shares of Haleon stock traded down GBX 57.40 during mid-day trading on Thursday, reaching GBX 316.60. 1,048,323,188 shares of the stock were exchanged, compared to its average volume of 32,679,883. The company has a market cap of £27.85 billion, a price-to-earnings ratio of 17.49, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. The firm has a 50-day simple moving average of GBX 353.77 and a 200 day simple moving average of GBX 360.62. Haleon has a fifty-two week low of GBX 310.50 and a fifty-two week high of GBX 433.60.

Haleon (LON:HLN) last released its quarterly earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. On average, sell-side analysts predict that Haleon will post 19.50 EPS for the current fiscal year.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon launched a £500 million share buyback, which should support earnings per share, return capital to investors and help fund employee share plans. Management also maintained its profit guidance. Haleon launches £500 million share buyback programme
• Neutral Sentiment: Third-quarter organic revenue increased 2.6%, while Haleon’s consumer-health portfolio continued to grow overall. However, the result was below management’s expectations, making the buyback appear more defensive than growth-driven. Haleon Q3 2026 trading update
• Negative Sentiment: Haleon reduced its fiscal 2026 organic revenue-growth forecast to approximately 2.5%, from a previous range of 3% to 5%. The downgrade reinforces investor concerns that sales momentum is slowing. Haleon trims 2026 growth outlook
• Negative Sentiment: Weaker-than-expected cough, cold and flu consumption reduced North American orders, while a raw-material classification change disrupted OTC-registered Centrum products in China. Haleon also expects a fourth-quarter revenue impact from accelerating a go-to-market change in Brazil. Haleon cuts revenue growth forecast

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.